SEC Company Response from ADC Therapeutics SA (ADCT) (CIK 0001771910) (ADCT) — May 12, 2020
ADC Therapeutics SA (ADCT) (CIK 0001771910)
Date: May 12, 2020 · CIK: 0001771910 · Accession: 0001140361-20-011410
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237841
Letter
Re: ADC Therapeutics SA
May 12, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. John Stickel
Registration Statement on Form F-1 (File No. 333-237841)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 737 copies of the Preliminary Prospectus dated May 11, 2020 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 3:30 p.m. Eastern Time, on Thursday, May 14, 2020 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Morgan Stanley & Co. LLC
Show Raw Text
CORRESP
1
filename1.htm
May 12, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. John Stickel
Re: ADC
Therapeutics SA
Registration Statement on Form F-1 (File No. 333-237841)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof,
approximately 737 copies of the Preliminary Prospectus dated May 11, 2020 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of
Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 3:30
p.m. Eastern Time, on Thursday, May 14, 2020 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Morgan Stanley & Co. LLC
BofA Securities, Inc.
Cowen and Company, LLC
As representatives of the Underwriters
By:
Morgan Stanley & Co. LLC
By:
/s/ Chris Rigoli
Name:
Chris Rigoli
Title:
Vice President
By:
BofA Securities, Inc.
By:
/s/ Michael Liloia
Name:
Michael Liloia
Title:
Director
By:
Cowen and Company, LLC
By:
/s/ Bill Follis
Name:
Bill Follis
Title:
Managing Director
[Signature Page to ADC Therapeutics SA Acceleration Request]